Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 560-568

  Jung, Chang Won ^a   Han, Kang Hee ^a   Seol, Hyesil ^a   Park, Sunhoo ^a   Koh, Jae Soo ^a   Lee, Seung Sook ^a   Kim, Min Joo ^a   Choi, Ik Joon ^a   Myung, Jae Kyung ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Anaplastic thyroid carcinoma (ATC); Cancer stem cell; Epithelial mesenchymal transition (EMT); Immunohistochemistry

Indexed keywords

TUMOR MARKER;

ADULT; AGED; CANCER STEM CELL; CARCINOMA, PAPILLARY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84923094333     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA and Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011; 30: 3153-3162.
2. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003; 15: 78-83.
3. Bernet V and Smallridge R. New therapeutic options for advanced forms of thyroid cancer. Expert Opin Emerg Drugs 2014; 19: 225-241.
4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
6. Thiery JP. [Epithelial-mesenchymal transitions in cancer onset and progression]. Bull Acad Natl Med 2009; 193: 1969-1978; discussion 1978-1969.
7. Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
8. Bates RC and Mercurio AM. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 2005; 4: 365-370.
9. Ahmed N, Abubaker K, Findlay J and Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10: 268-278.
10. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H and Becker KF. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891.
11. Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H and Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 2013; 26: 54-61.
12. Salerno P, Garcia-Rostan G, Piccinin S, Bencivenga TC, Di Maro G, Doglioni C, Basolo F, Maestro R, Fusco A, Santoro M and Salvatore G. TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. J Clin Endocrinol Metab 2011; 96: E772-781.
13. Hardy RG, Vicente-Duenas C, Gonzalez-Herrero I, Anderson C, Flores T, Hughes S, Tselepis C, Ross JA and Sanchez-Garcia I. Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Pathol 2007; 171: 1037-1046.
14. Zavadil J. A spotlight on regulatory networks connecting EMT and cancer stem cells. Cell Cycle 2010; 9: 2927.
15. Kong D, Li Y, Wang Z and Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) 2011; 3: 716-729.
16. Singh A and Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
17. Fuxe J, Vincent T and Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010; 9: 2363-2374.
18. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262.
19. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM and Sobrinho-Simoes M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 247-251.
20. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA and Nikiforov YE. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-5404.
21. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V and Yamashita S. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007; 148: 1797-1803.
22. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A and Giordano C. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 2008; 3: e3544.
23. Friedman S, Lu M, Schultz A, Thomas D and Lin RY. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 2009; 4: e5395.